Binge Eating Disorder - Pipeline Review, H1 2020
Binge Eating Disorder - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Binge Eating Disorder - Pipeline Review, H1 2020, provides an overview of the Binge Eating Disorder (Central Nervous System) pipeline landscape.
Binge eating disorder is a serious condition characterized by uncontrollable eating and resulting weight gain. The causes of binge-eating disorder are unknown. But family history, biological factors, long-term dieting and psychological issues increase risk. Signs and symptoms include eating unusually large amounts of food, frequently eating alone, feeling that eating behavior is out of control and experiencing depression and anxiety. Treatment includes psychotherapy, medications and behavioral weight-loss programs.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Binge Eating Disorder - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Binge Eating Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Binge Eating Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Binge Eating Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase I, Preclinical and Discovery stages are 1, 2, 6 and 1 respectively.
Binge Eating Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Binge Eating Disorder - Pipeline Review, H1 2020, provides an overview of the Binge Eating Disorder (Central Nervous System) pipeline landscape.
Binge eating disorder is a serious condition characterized by uncontrollable eating and resulting weight gain. The causes of binge-eating disorder are unknown. But family history, biological factors, long-term dieting and psychological issues increase risk. Signs and symptoms include eating unusually large amounts of food, frequently eating alone, feeling that eating behavior is out of control and experiencing depression and anxiety. Treatment includes psychotherapy, medications and behavioral weight-loss programs.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Binge Eating Disorder - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Binge Eating Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Binge Eating Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Binge Eating Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase I, Preclinical and Discovery stages are 1, 2, 6 and 1 respectively.
Binge Eating Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Binge Eating Disorder (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Binge Eating Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Binge Eating Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Binge Eating Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Binge Eating Disorder (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Binge Eating Disorder (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Binge Eating Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Binge Eating Disorder - Overview
Binge Eating Disorder - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Binge Eating Disorder - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Binge Eating Disorder - Companies Involved in Therapeutics Development
Amygdala Neurosciences Inc
Chronos Therapeutics Ltd
F. Hoffmann-La Roche Ltd
Omeros Corp
OXonium Therapeutics
Seropeutics LLC
Sosei Heptares
Sunovion Pharmaceuticals Inc
Vivus Inc
Binge Eating Disorder - Drug Profiles
(phentermine hydrochloride + topiramate) ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANS-6637 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-010018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTDP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dasotraline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Antagonize Ox1 Receptor for Binge Eating Disorder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-5256390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SERx-480 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Binge Eating Disorder - Dormant Projects
Binge Eating Disorder - Discontinued Products
Binge Eating Disorder - Product Development Milestones
Featured News & Press Releases
Nov 20, 2019: New Clinical data demonstrate VIVUS’ Qsymia is effective at reducing Binge Eating in patients with Binge-Eating Disorder or Bulimia Nervosa
Jul 30, 2019: Sunovion announces acceptance by the U.S. FDA of the new drug application for Dasotraline for the treatment of adults with moderate-to-severe binge eating disorder
May 02, 2019: Sunovion to present data on dasotraline at the 2019 American Psychiatric Association Annual Meeting
Jul 25, 2018: Sunovion announces positive top-line results from pivotal study evaluating Dasotraline in adults with binge eating disorder
May 02, 2018: Chronos Therapeutics announces positive pre-clinical proof of concept studies for its Orexin-1 antagonist project initially targeting binge eating disorder
May 02, 2018: Sunovion to Present Data on dasotraline at the 2018 American Psychiatric Association Annual Meeting
Sep 14, 2017: Sunovion to Present Data on Dasotraline at the 2017 Psych Congress
Aug 31, 2017: Sunovion Submits New Drug Application for Dasotraline to the FDA for the Treatment of Patients with ADHD
May 23, 2017: Sunovion Announces Positive Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Adults with Binge Eating Disorder at Annual American Psychiatric Association Meeting
May 16, 2017: Sunovion to Present Data on Dasotraline at Annual American Psychiatric Association Meeting Showcase
Jan 13, 2017: Sunovion Announces Top-line Results from Studies Evaluating Dasotraline in Adults with Binge Eating Disorder and Attention Deficit Hyperactivity Disorder
Oct 06, 2016: Study Finds New Approach to Block Binge Eating
Jan 25, 2016: Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Binge Eating Disorder - Overview
Binge Eating Disorder - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Binge Eating Disorder - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Binge Eating Disorder - Companies Involved in Therapeutics Development
Amygdala Neurosciences Inc
Chronos Therapeutics Ltd
F. Hoffmann-La Roche Ltd
Omeros Corp
OXonium Therapeutics
Seropeutics LLC
Sosei Heptares
Sunovion Pharmaceuticals Inc
Vivus Inc
Binge Eating Disorder - Drug Profiles
(phentermine hydrochloride + topiramate) ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANS-6637 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-010018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTDP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dasotraline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Antagonize Ox1 Receptor for Binge Eating Disorder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-5256390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SERx-480 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Binge Eating Disorder - Dormant Projects
Binge Eating Disorder - Discontinued Products
Binge Eating Disorder - Product Development Milestones
Featured News & Press Releases
Nov 20, 2019: New Clinical data demonstrate VIVUS’ Qsymia is effective at reducing Binge Eating in patients with Binge-Eating Disorder or Bulimia Nervosa
Jul 30, 2019: Sunovion announces acceptance by the U.S. FDA of the new drug application for Dasotraline for the treatment of adults with moderate-to-severe binge eating disorder
May 02, 2019: Sunovion to present data on dasotraline at the 2019 American Psychiatric Association Annual Meeting
Jul 25, 2018: Sunovion announces positive top-line results from pivotal study evaluating Dasotraline in adults with binge eating disorder
May 02, 2018: Chronos Therapeutics announces positive pre-clinical proof of concept studies for its Orexin-1 antagonist project initially targeting binge eating disorder
May 02, 2018: Sunovion to Present Data on dasotraline at the 2018 American Psychiatric Association Annual Meeting
Sep 14, 2017: Sunovion to Present Data on Dasotraline at the 2017 Psych Congress
Aug 31, 2017: Sunovion Submits New Drug Application for Dasotraline to the FDA for the Treatment of Patients with ADHD
May 23, 2017: Sunovion Announces Positive Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Adults with Binge Eating Disorder at Annual American Psychiatric Association Meeting
May 16, 2017: Sunovion to Present Data on Dasotraline at Annual American Psychiatric Association Meeting Showcase
Jan 13, 2017: Sunovion Announces Top-line Results from Studies Evaluating Dasotraline in Adults with Binge Eating Disorder and Attention Deficit Hyperactivity Disorder
Oct 06, 2016: Study Finds New Approach to Block Binge Eating
Jan 25, 2016: Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Binge Eating Disorder, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Binge Eating Disorder - Pipeline by Amygdala Neurosciences Inc, H1 2020
Binge Eating Disorder - Pipeline by Chronos Therapeutics Ltd, H1 2020
Binge Eating Disorder - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Binge Eating Disorder - Pipeline by Omeros Corp, H1 2020
Binge Eating Disorder - Pipeline by OXonium Therapeutics, H1 2020
Binge Eating Disorder - Pipeline by Seropeutics LLC, H1 2020
Binge Eating Disorder - Pipeline by Sosei Heptares, H1 2020
Binge Eating Disorder - Pipeline by Sunovion Pharmaceuticals Inc, H1 2020
Binge Eating Disorder - Pipeline by Vivus Inc, H1 2020
Binge Eating Disorder - Dormant Projects, H1 2020
Binge Eating Disorder - Discontinued Products, H1 2020
Number of Products under Development for Binge Eating Disorder, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Binge Eating Disorder - Pipeline by Amygdala Neurosciences Inc, H1 2020
Binge Eating Disorder - Pipeline by Chronos Therapeutics Ltd, H1 2020
Binge Eating Disorder - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Binge Eating Disorder - Pipeline by Omeros Corp, H1 2020
Binge Eating Disorder - Pipeline by OXonium Therapeutics, H1 2020
Binge Eating Disorder - Pipeline by Seropeutics LLC, H1 2020
Binge Eating Disorder - Pipeline by Sosei Heptares, H1 2020
Binge Eating Disorder - Pipeline by Sunovion Pharmaceuticals Inc, H1 2020
Binge Eating Disorder - Pipeline by Vivus Inc, H1 2020
Binge Eating Disorder - Dormant Projects, H1 2020
Binge Eating Disorder - Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development for Binge Eating Disorder, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Amygdala Neurosciences Inc
Chronos Therapeutics Ltd
F. Hoffmann-La Roche Ltd
Omeros Corp
OXonium Therapeutics
Seropeutics LLC
Sosei Heptares
Sunovion Pharmaceuticals Inc
Vivus Inc
Number of Products under Development for Binge Eating Disorder, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Amygdala Neurosciences Inc
Chronos Therapeutics Ltd
F. Hoffmann-La Roche Ltd
Omeros Corp
OXonium Therapeutics
Seropeutics LLC
Sosei Heptares
Sunovion Pharmaceuticals Inc
Vivus Inc
